The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Case Report: A Non-Tuberculous Mycobacterial Infection

Case Report: A Non-Tuberculous Mycobacterial Infection

January 20, 2021 • By Bradley Bohman, MD, & Jawad Bilal, MBBS

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Magnetic resonance imaging of the patient’s left knee shows joint effusion, synovial thickening, and periarticular muscle and soft tissue edema.

Figure 1. Magnetic resonance imaging of the patient’s left knee shows joint effusion, synovial thickening, and periarticular muscle and soft tissue edema.

Tumor necrosis factor-α inhibitors (TNFi’s) have emerged as an integral part of therapeutic strategies for several rheumatic diseases. TNF-α is a pro-inflammatory cytokine implicated in the pathogenesis of rheumatoid arthritis (RA), seronegative spondyloarthropathies and inflammatory bowel disease (IBD). It also plays a central role in the immune response to mycobacterial infection. 

You Might Also Like
  • Case Report: Does She Have a Fungal Infection or Autoimmune Disease?
  • Fellow’s Forum Case Report: New Sarcoidosis Cases in Patients Treated with Tumor Necrosis Factor–Alpha Inhibitors
  • Case Report: Is It Reactive or IBD-Associated Arthritis?
Explore This Issue
January 2021

Many biologic agents, particularly TNFi’s, are associated with an increased risk of tuberculosis; however, the risk of non-tuberculous mycobacterial infections among patients treated with a TNFi has not been studied extensively. 

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

We present this report on a patient with sarcoidosis receiving TNFi therapy who developed a disseminated non-tuberculous mycobacterial infection.

Case History

A 69-year-old man presented to the clinic with symptoms of progressively worsening left knee pain, stiffness and swelling over six months. He was unable to bear weight on the affected leg and was wheelchair bound. He had previously been diagnosed with both neurosarcoidosis and osteo­arthritis. He had initially been treated with glucocorticoid monotherapy. Because he deteriorated clinically, 400 mg of intra­venous (IV) infliximab every six weeks and 500 mg of mycophenolate mofetil twice a day orally were added to his medical regimen.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

His knee had initially been evaluated by his primary care provider; plain radiographs of the knees demonstrated osteo­arthritis. Subsequently, he was referred to a sports medicine specialist and an orthopedic surgeon for further evaluation. Oral analgesics, intra-articular steroid injection and physical therapy provided him with no relief, and he was referred to our division for further evaluation.

In our clinic, he was afebrile; his blood pressure was 152/82 mmHg, and his heart rate was 66 bpm. His left knee was swollen, and both passive and active movements were limited by pain.

Laboratory tests on his initial presentation demonstrated leukocytosis; his white blood cell count was 13,200/uL with 86% neutrophils. His complete metabolic panel and urinalysis were unremarkable. Rheum­atoid factor, anti-cyclic citrullinated protein antibodies and anti-double stranded DNA antibodies were not detected on immunological studies. Tests for Borrelia and Coccidioides IgG and IgM antibodies were negative. 

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Magnetic resonance imaging (MRI) of the left knee joint revealed a moderate joint effusion with diffuse synovial thickening, and periarticular muscle and soft tissue edema (see Figure 1, above). 

Synovial fluid aspirate demonstrated 8,935 nucleated cells (70% mononuclear) with Mycobacterium avium-intra­cellulare growth in modified Middlebrook 7H9 broth, a liquid growth medium used to culture Mycobacterium. 

Infliximab was stopped, and the patient was treated with ethambutol and azithromycin.

Over the next month, the patient noticed low-grade fever, malaise, night sweats and unintentional weight loss of 10 lbs. He underwent open synovectomy of the left knee. The synovial tissue demonstrated an active granulomatous synovitis (see Figure 2, and synovial cultures grew Mycobacterium avium complex (MAC). 

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Systemic Inflammatory Syndromes Tagged With: bacteria, case report, Infection, tumor necrosis factor inhibitor (TNFi)Issue: January 2021

You Might Also Like:
  • Case Report: Does She Have a Fungal Infection or Autoimmune Disease?
  • Fellow’s Forum Case Report: New Sarcoidosis Cases in Patients Treated with Tumor Necrosis Factor–Alpha Inhibitors
  • Case Report: Is It Reactive or IBD-Associated Arthritis?
  • Rheumatoid Arthritis Patients on Biologics Remain At Risk of Infection

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.